• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Acacia Pharma - Articles and news items

Acacia Pharma’s antiemetic drug prevents post-op nausea and vomiting

Industry news / 12 August 2016 / Acacia Pharma

Acacia Pharma’s phase 3 trial, comprised of 568 patients, compared two doses of Baremsis (amisulpride injection, formerly APD421), a dopamine D2/D3 antagonist antiemetic, against placebo in patients with established nausea and/or vomiting after surgery (PONV), who had not previously received any prophylactic antiemetics…

Positive results for Baremsis in Phase 3 PONV study

Industry news / 5 January 2016 / Victoria White

Baremsis comprises a low dose intravenous formulation of the marketed dopamine antagonist amisulpride, which Acacia Pharma has repurposed for the management of PONV…

Positive results from Phase 2 study of APD403 in chemotherapy-induced nausea & vomiting

Industry news / 6 May 2015 /

Acacia Pharma has announced positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV)…